Abstract
Get full access to this article
View all access options for this article.
References
1.
Kay
J
Schoels
MM
Dörner
T
, et al . Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases . Ann Rheum Dis 2018 ; 77 (2 ): 165 –174 .
2.
Steinberg
J
Fragoso
YD
Duran Quiroz
JC
, et al . Practical issues concerning the approval and use of biosimilar drugs for the treatment of multiple sclerosis in Latin America . Neurol Ther 2019 ; 8 (2 ): 207 –214 .
3.Food Drug Administration (FDA), Center for Drug Evaluation Research 644 (CDER), Center for Biologics Evaluation Research (CBER) . Considerations in demonstrating interchangeability with a reference product: Guidance for industry , https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-demonstrating-interchangeability-reference-product-guidance-industry (2019 , accessed 1 July 2022 ).
4.
Gough
S.
Post-marketing surveillance: A UK/European perspective . Curr Med Res Opin 2005 ; 21 (4 ): 565 –570 .
5.
Rivera
VM.
Biosimilar drugs for multiple sclerosis: An unmet international need or a regulatory risk? Neurol Ther 2019 ; 8 (2 ): 177 –184 .